JPH0242078A - Condensed heterocyclic compound - Google Patents
Condensed heterocyclic compoundInfo
- Publication number
- JPH0242078A JPH0242078A JP19365688A JP19365688A JPH0242078A JP H0242078 A JPH0242078 A JP H0242078A JP 19365688 A JP19365688 A JP 19365688A JP 19365688 A JP19365688 A JP 19365688A JP H0242078 A JPH0242078 A JP H0242078A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- acid
- solvent
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- -1 (substituted) amino Chemical group 0.000 abstract description 86
- 150000001875 compounds Chemical class 0.000 abstract description 40
- 239000002904 solvent Substances 0.000 abstract description 15
- 229910052736 halogen Inorganic materials 0.000 abstract description 4
- 150000002367 halogens Chemical class 0.000 abstract description 4
- 239000003223 protective agent Substances 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 238000001356 surgical procedure Methods 0.000 abstract description 3
- 208000006011 Stroke Diseases 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000022540 Consciousness disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000013078 crystal Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000000496 anti-anoxic effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WVVHWHZTKGVNGY-UHFFFAOYSA-N 2-(2-benzyl-3-oxo-1H-isoindol-1-yl)acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)N1CC1=CC=CC=C1 WVVHWHZTKGVNGY-UHFFFAOYSA-N 0.000 description 1
- XEFXQIBENKOFCP-UHFFFAOYSA-N 2-benzyl-3-hydroxy-3h-isoindol-1-one Chemical compound O=C1C2=CC=CC=C2C(O)N1CC1=CC=CC=C1 XEFXQIBENKOFCP-UHFFFAOYSA-N 0.000 description 1
- SCSQXWFIZNVBID-UHFFFAOYSA-N 2-benzyl-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 SCSQXWFIZNVBID-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
葭!上Δ机皿立」
本発明は、医薬として有用な新規縮合複素環化合物に関
する。[Detailed description of the invention] Yoshi! FIELD OF THE INVENTION The present invention relates to novel fused heterocyclic compounds useful as pharmaceuticals.
従来の技術
で表わされる化合物、また
ヘテロサイクルズ(lIeLerocycles)
I 9 、49(1982)には、
式
で表わされる化合物およびそれらの合成法がそれぞれ記
載されているが、抗アノキシア作用などの生物活性につ
いては何ら開示されていない。Compounds represented by conventional techniques, also heterocycles
I 9 , 49 (1982) describes compounds represented by the following formulas and their synthesis methods, but does not disclose any biological activity such as anti-anoxia action.
一方、抗アノキシア作用を有する化合物としては、例え
ば特開昭61−30587号公報に記載された化合物な
どが知られている。On the other hand, as a compound having an anti-anoxia effect, for example, a compound described in JP-A-61-30587 is known.
発明が解決しようとする課題
本発明は、抗アノキシア作用を何することが知られてい
る公知の化合物に比べて、より強い抗アノキシア作用を
有する化合物を提供するものである。Problems to be Solved by the Invention The present invention provides a compound that has a stronger anti-anoxic effect compared to known compounds that are known to have anti-anoxic effects.
課題を解決するための手段
本発明者らは、抗アノキシア作用を有し、とりわけ脳保
護剤として有用な化合物の検索に鋭2α努力を重ねた結
果、一般式(1)
[式中、X、Yはそれぞれ水素原子又は置換JI(を示
し、Zは置換されていてもよいアミノ基を示し、nは0
〜2の整数を示す。]で表わされる縮合複素環化合物お
よびその塩の創製に成功するとともに、これらの化合物
が優れた脳保護作用を示すことを知見し、これに基づい
てさらに研究を進め本発明を完成するに至った。Means for Solving the Problems The present inventors have made intensive efforts to search for compounds having anti-anoxia action and are particularly useful as brain protective agents. Y each represents a hydrogen atom or a substituted JI (, Z represents an optionally substituted amino group, n is 0
Indicates an integer between ~2. In addition to successfully creating a fused heterocyclic compound represented by .
すなわち、本発明は、式(1)で示される化合物(化合
物(1))又はその塩である。より具体的には、化合物
(1)またはその塩、それらの製法及びそれらを含有4
゛る抗アノキンア剤または脳保護剤に関する。That is, the present invention is a compound represented by formula (1) (compound (1)) or a salt thereof. More specifically, compound (1) or its salt, their production method, and 4 containing them.
The present invention relates to an anti-anoquinone or brain-protecting agent.
前記式(りにおいて、X、Yで示される置換基としては
、たとえばハロゲン(フッ素、塩素、臭素ヨウ素)、低
級アルキル(例、メチル。エチル、プロピル、ブチルな
どの01−、アルキル)、低級アルコキシ(例、メトキ
ン、エトキシ、プロポキシなどのC1−3アルコキシ)
、ニトロ、アミノ、ヒドロキシルがあげられる。In the above formula, the substituents represented by (For example, C1-3 alkoxy such as metquin, ethoxy, propoxy)
, nitro, amino, and hydroxyl.
前記式(1)において、Zで示される置換されていてら
よいアミノ法は無置換のアミノW、モノ置換アミノ基お
よびジ置換アミノ基のいずれでらる。In the above formula (1), the optionally substituted amino group represented by Z can be an unsubstituted amino W, a mono-substituted amino group or a di-substituted amino group.
上記式(a)において、R,およびR2で示される置換
基としては、たとえば低級アルキル(例、メチル、エチ
ル。プロピル、イソプロピルなど炭素数1〜4のもの)
、フェニルアルキル(例、ベンジル。In the above formula (a), the substituents represented by R and R2 include, for example, lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. having 1 to 4 carbon atoms)
, phenylalkyl (e.g., benzyl).
フェネチル、1−フェニルエチルなどフェニルC3−4
アルキル)、炭素数5〜7のシクロアルキル(例、シク
ロペンチル、シクロヘキシル、シクロヘキシル)、ω−
ヒドロキシアルキル(例、2−ヒドロキシエチル。3−
ヒドロキシプロピル、4−ヒドロキシブチル。5−ヒド
ロキシペンチルなどω−ヒドロキシC2−、アルキル)
、ω−ジアルキルアミノアルキル(例、ジメチルアミノ
メチル、ジプロピルアミノメチル、ジメチルアミノエチ
ル、ジエチルアミノエチル、ジプロピルアミノエチル、
ジブチルアミノエチル、ジエチルアミノエチル、ジエチ
ルアミノプロピル、ジメヂルアミノブチル、メヂルエチ
ルアミノメヂル、メヂルプロピルアミノエチルなどω−
フジC1−,アルキルアミノC14アルキル)。Phenyl C3-4 such as phenethyl and 1-phenylethyl
alkyl), cycloalkyl having 5 to 7 carbon atoms (e.g., cyclopentyl, cyclohexyl, cyclohexyl), ω-
Hydroxyalkyl (e.g. 2-hydroxyethyl.3-
Hydroxypropyl, 4-hydroxybutyl. ω-hydroxyC2-, alkyl such as 5-hydroxypentyl)
, ω-dialkylaminoalkyl (e.g., dimethylaminomethyl, dipropylaminomethyl, dimethylaminoethyl, diethylaminoethyl, dipropylaminoethyl,
Dibutylaminoethyl, diethylaminoethyl, diethylaminopropyl, dimethylaminobutyl, methylethylaminomethyl, methylpropylaminoethyl, etc. ω-
Fuji C1-, alkylamino C14 alkyl).
環状アミノアルキル(例、ピロリジノメチル。ピペリジ
ノメチル、ヘキサメチレンイミノメヂル、2(ピロリジ
ノ)エチル、2−(ピペリジノ)エチル、2−(ヘキサ
メチレンイミノ)エチル、3−(ピロリジノ)プロピル
、3−(ピペリジノ)プロピル、3−(ヘキサメチレン
イミノ)プロピル、4−(ピロリジノ)ブチル、4−(
ピペリジノ)ブチル、4−(ヘキサメチレンイミノ)ブ
チル、4−(2−ピリミジニル)ビベラジノメヂル、2
−[4−(2−ピリミジニル)ピペラジノ]エチル、3
−[4−(2−ピリミジニル)ピペラジノコプロピル、
4−[4−(2−ピリミジニル)ピペラジノコブチル、
5−[4−(2−ピリミジニル)ピペラジノコペンチル
、6−[4−(2−ピリミジニル)ピペラジノコヘキシ
ルなどの環状アミノC+−uアルキル)、(N−アルキ
ル−環状アミニル)アルキル(例、(N−メチルピロリ
ジン−2−イル)メチル、(N−エチルピロリジン−2
−イル)メチル、(N−プロピルピロリジン−2−イル
)メチル。Cyclic aminoalkyl (e.g., pyrrolidinomethyl; piperidinomethyl, hexamethyleneiminomethyl, 2(pyrrolidino)ethyl, 2-(piperidino)ethyl, 2-(hexamethyleneimino)ethyl, 3-(pyrrolidino)propyl, 3-( piperidino)propyl, 3-(hexamethyleneimino)propyl, 4-(pyrrolidino)butyl, 4-(
piperidino)butyl, 4-(hexamethyleneimino)butyl, 4-(2-pyrimidinyl)biverazinomedyl, 2
-[4-(2-pyrimidinyl)piperazino]ethyl, 3
-[4-(2-pyrimidinyl)piperazinocopropyl,
4-[4-(2-pyrimidinyl)piperazinocobutyl,
5-[4-(2-pyrimidinyl)piperazinocopentyl, 6-[4-(2-pyrimidinyl)piperazinocohexyl, etc. cyclic amino C+-u alkyl), (N-alkyl-cyclic aminyl)alkyl (e.g. , (N-methylpyrrolidin-2-yl)methyl, (N-ethylpyrrolidin-2-yl)
-yl)methyl, (N-propylpyrrolidin-2-yl)methyl.
(N−ブチルピロリジン−2−イル)メチル、(N−メ
チルピロリジン−2−イル)エチル、(N−エチルピロ
リジン−2−イル)エチル、(N−プロピルピロリジン
−2−イル)エチル、(N−ブチルピロリジン−2−イ
ル)エチル、(N−メチルピロリジン−2−イル)プロ
ピル、(N−エチルピロリジン−2−イル)プロピル、
(N−プロピルピロリジン−2−イル)プロピル、(N
−メチルピロリジン−2−イル)ブチル、(N−エチル
ピロリジン−2−イル)ブチル、(N−プロピルピロリ
ジン−2−イル)ブチル、(N−ブチルピロリジン−2
−イル)ブチル、(N−メチルピペリジン−2(又は4
)−イル)メチル、(N−エチルピペリジン−2(又は
4)−イル)メチル、(N−プロピルピペリジン−2(
又は4)−イル)メチル、(N−ブチルピペリジン−2
(又は4)−イル)メチル、(N−メチルピペリジン−
2(又は4)−イル)エチル、(N−エチルピペリジン
−2(又は4)−イル)エチル、(N−プロピルピペリ
ジン−2(又は4)−イル)エチル、(N−ブチルピペ
リジン−2(又は4)−イル)エチル、(N−メチルピ
ペリジン−2(又は4)−イル)プロピル、(Nエチル
ピペリジン−2(又は4)−イル)プロピル。(N-Butylpyrrolidin-2-yl)methyl, (N-methylpyrrolidin-2-yl)ethyl, (N-ethylpyrrolidin-2-yl)ethyl, (N-propylpyrrolidin-2-yl)ethyl, (N- -butylpyrrolidin-2-yl)ethyl, (N-methylpyrrolidin-2-yl)propyl, (N-ethylpyrrolidin-2-yl)propyl,
(N-propylpyrrolidin-2-yl)propyl, (N
-methylpyrrolidin-2-yl)butyl, (N-ethylpyrrolidin-2-yl)butyl, (N-propylpyrrolidin-2-yl)butyl, (N-butylpyrrolidin-2-yl)
-yl)butyl, (N-methylpiperidine-2(or 4)
)-yl)methyl, (N-ethylpiperidin-2(or 4)-yl)methyl, (N-propylpiperidin-2(
or 4)-yl)methyl, (N-butylpiperidine-2
(or 4)-yl)methyl, (N-methylpiperidine-
2(or 4)-yl)ethyl, (N-ethylpiperidin-2(or 4)-yl)ethyl, (N-propylpiperidin-2(or 4)-yl)ethyl, (N-butylpiperidin-2( or 4)-yl)ethyl, (N-methylpiperidin-2(or 4)-yl)propyl, (N-ethylpiperidin-2(or 4)-yl)propyl.
(N−プロピルピペリジン−2(又は4)−イル)プロ
ピル、(N−ブチルピペリジン−2(又は4)−イル)
プロピル、(N−メチルピペリジン−2(又は4)−イ
ル)ブチル、(N−エチルピペリジン−2(又は4)−
イル)ブチル、(N−プロピルピペリジン−2(又は4
)−イル)ブチル、(N−ブチルピペリジン−2(又は
4)−イル)ブチル、(N−メチルへキサヒドロアゼピ
ン−2−イル)メチル、(N−エチルへキサヒドロアゼ
ピン−2−イル)メチル、(Nプロピルへキサヒドロア
ゼピン−2−イル)メチル、(N−ブチルヘキサヒドロ
アゼピン−2−イル)メチル、(N−メチルへキサヒド
ロアゼピン−2−イル)エチル、(N−エチルへギザヒ
ドロアゼピン−2−イル)エチル、(N−プロピルへキ
サヒドロアゼピン−2−イル)エチル、(N−ブチルヘ
キサヒドロアゼピン−2−イル)エチル、(N−メチル
ヘキサヒドロアゼピン−2−イル)プロピル、(N−エ
チルへキサヒドロアゼピン−2−イル)プロピル、(N
−プロピルへキサヒドロアゼピン−2−イル)プロピル
、(N−ブチルヘキサヒドロアゼピン−2−イル)プロ
ピル、(N−メチルへキサヒドロアゼピン−2−イル)
ブチル、(N−エチルへギザヒドロアゼピン−2−イル
)ブチル、(N−プロピルへキサヒドロアゼピン−2−
イル)ブチル、(Nブチルヘキサヒドロアゼピン−2−
イル)ブチルなどのN −C+−4アルキル−環状アミ
ニルC1−。(N-propylpiperidin-2(or 4)-yl)propyl, (N-butylpiperidin-2(or 4)-yl)
Propyl, (N-methylpiperidin-2(or 4)-yl)butyl, (N-ethylpiperidin-2(or 4)-yl)
yl)butyl, (N-propylpiperidine-2(or 4)
)-yl)butyl, (N-butylpiperidin-2(or 4)-yl)butyl, (N-methylhexahydroazepin-2-yl)methyl, (N-ethylhexahydroazepin-2-yl) Methyl, (N-propylhexahydroazepin-2-yl)methyl, (N-butylhexahydroazepin-2-yl)methyl, (N-methylhexahydroazepin-2-yl)ethyl, (N-ethyl) Gizahydroazepin-2-yl)ethyl, (N-propylhexahydroazepin-2-yl)ethyl, (N-butylhexahydroazepin-2-yl)ethyl, (N-methylhexahydroazepin-2-yl) ) propyl, (N-ethylhexahydroazepin-2-yl)propyl, (N
-Propylhexahydroazepin-2-yl)propyl, (N-butylhexahydroazepin-2-yl)propyl, (N-methylhexahydroazepin-2-yl)
Butyl, (N-ethylhexahydroazepin-2-yl)butyl, (N-propylhexahydroazepin-2-yl)
yl)butyl, (N-butylhexahydroazepine-2-
yl) butyl and the like.
アルキル)、置換基を有していてもよいフェニル(例、
4−クロロフェニル、4−ヒドロキシフェニル、4−メ
トキシフェニル84−ニトロフェニル。alkyl), phenyl which may have substituents (e.g.
4-chlorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl 84-nitrophenyl.
4−メトキシカルボニルフェニル、4−(ジメチルアミ
ノフェニル)など)、置換基を有していてもよいチアゾ
リル(例、3−クロロチアゾリル、4−ヒドロキシチア
ゾリルなど)、置換基を有していてもよいチアゾリニル
(例、4−ブロモチアゾリニル。4-methoxycarbonylphenyl, 4-(dimethylaminophenyl), etc.), thiazolyl which may have a substituent (e.g., 3-chlorothiazolyl, 4-hydroxythiazolyl, etc.), even if it has a substituent Good thiazolinyl (e.g. 4-bromothiazolinyl).
3−ヒドロキシチアゾリニル、3−ニトロチアゾリニル
など)、置換基を有していてもよいベンズヒドリル[例
、ジ(4−フルオロフェニル)メチル、ジ(4−メトキ
シフェニル)メチル、ジ(4−メチルフェニル)メチル
など]などがあげられる。3-hydroxythiazolinyl, 3-nitrothiazolinyl, etc.), optionally substituted benzhydryls [e.g., di(4-fluorophenyl)methyl, di(4-methoxyphenyl)methyl, di(4-fluorophenyl)methyl, di(4-fluorophenyl)methyl, di(4-methoxyphenyl)methyl, etc. -methylphenyl)methyl, etc.].
上記式(a)において、R1とR2が結合して環を形成
し、Zで示される置換されていてもよいアミノ基が環状
アミノ基であってらよい。該環状アミノ基の環状アミノ
は環をも14成する原子として少なくとも1個の窒素原
子を有する5〜7員環で窒素原子を介して結合J−る基
であり、環を構成4゛ろ原子としては窒素原子の他に酸
素原子、硫黄原子などのへテロ原子を含んでいてもよい
。該環状アミノ基の具体例としては、ピロリジニル、ピ
ペリジニル、ピペラジニル、モルホリノ、チアゾリジニ
ル。In the above formula (a), R1 and R2 may combine to form a ring, and the optionally substituted amino group represented by Z may be a cyclic amino group. The cyclic amino of the cyclic amino group is a 5- to 7-membered ring having at least one nitrogen atom as an atom constituting the ring, and is a group bonded via the nitrogen atom, and the 4 atoms constituting the ring are may contain a heteroatom such as an oxygen atom or a sulfur atom in addition to a nitrogen atom. Specific examples of the cyclic amino group include pyrrolidinyl, piperidinyl, piperazinyl, morpholino, and thiazolidinyl.
ヘキサヒドロアゼピニルなどがあげられる。これらの環
状アミノ基は環上の任意の位置に1−2個の置換基を有
していてもよく、かかる置換」□(とじては、たとえば
、オキソ、ヒドロキシル、ω−ヒト【lキシC3−4ア
ルキル(例、ヒドロキシメチル、2−ヒドロキシエチル
、3−ヒドロキシプロピル、4−ヒドロキシブチル、2
−ヒドロキシ−2−メチルプロビル)、C+−4アルキ
ル(例、メチル、エチル。Examples include hexahydroazepinyl. These cyclic amino groups may have 1-2 substituents at any position on the ring, and examples of such substitutions include oxo, hydroxyl, ω-human [lxyC3 -4 alkyl (e.g. hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 2-hydroxybutyl,
-hydroxy-2-methylpropyl), C+-4 alkyl (e.g. methyl, ethyl.
プロピル、ブチル、イソプロピル)、フェニルC2−4
アルキル(例、ベンジル、フェネチル、α−メチルベン
ジル)、C*−sアルコキシカルボニル(例ぐメトキン
カルボニル、エトキシカルボニル、プロポキシカルボニ
ル、ブトキシカルボニル)、アルキレンジオキシ(例、
メヂレンジオキシ、エチレンジオキシ)。propyl, butyl, isopropyl), phenyl C2-4
Alkyl (e.g., benzyl, phenethyl, α-methylbenzyl), C*-s alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl), alkylenedioxy (e.g.,
medylendioxy, ethylenedioxy).
フェニル、ピペリジニル、ピリジル、シクロアルキル(
例、シクロペンチル、シクロへキシルシクロへブチル)
、ベンズヒドリル、ピリミジニル、ピロリジノカルボニ
ルCI−4アルキル(例、ピロリジノ力ルポニルメヂル
、ピロリツノカルボニルエチル)ベンゾイミダゾリニル
などがあげられ、これらのうち環状Jル(例、フェニル
など)はさらに、ハロゲン(例、塩素、臭素、フッ素、
ヨウ素)、ヒドロキシ。Phenyl, piperidinyl, pyridyl, cycloalkyl (
e.g., cyclopentyl, cyclohexylcyclohebutyl)
, benzhydryl, pyrimidinyl, pyrrolidinocarbonyl CI-4 alkyl (e.g., pyrrolidinocarbonyl, pyrrolidinocarbonylethyl), benzimidazolinyl, etc. Among these, cyclic compounds (e.g., phenyl, etc.) are further combined with halogen ( Examples: chlorine, bromine, fluorine,
iodine), hydroxy.
ニトロ、C,−、アルキル(例、メチル、エチル、プロ
ピル)、C+−、アルコキシ(例、メトキシ、エトキシ
、プロポキシ8ブトキシ)、トリフルオロメチル+ C
I−4アルキルカルボニル(例、メチルカルボニル、エ
チルカルボニル、プロピルカルボニル)などの置換基を
aしていてらよい。Nitro, C, -, alkyl (e.g. methyl, ethyl, propyl), C+-, alkoxy (e.g. methoxy, ethoxy, propoxy 8-butoxy), trifluoromethyl + C
I-4 Substituents such as alkylcarbonyl (eg, methylcarbonyl, ethylcarbonyl, propylcarbonyl) may be a-substituted.
前記式(1)で示される化合物のなかでも、式(1)r
lx、yがそれぞれ水素原子を示し、Zがジメチルアミ
ノ、ジエチルアミノなどのジC1−3アルキルアミノ基
を示し、nが0またはIを示ず化合物が好ましい。Among the compounds represented by the formula (1), formula (1) r
A compound in which lx and y each represent a hydrogen atom, Z represents a di-C1-3 alkylamino group such as dimethylamino or diethylamino, and n represents 0 or I is preferred.
化合物(1)は酸付加塩、とりわけ薬理学的に許容され
る酸付加塩を形成していてもよく、それらの塩としては
、たとえば無機酸(例、塩酸、硝酸。Compound (1) may form an acid addition salt, especially a pharmacologically acceptable acid addition salt, and these salts include, for example, inorganic acids (eg, hydrochloric acid, nitric acid).
リン酸、臭化水素酸、硫酸など)、あるいは有機酸(酢
酸、ギ酸、プロピオン酸、フマル酸、マレイン酸、コハ
ク酸、酒石酸、クエン酸、リンゴ酸、蓚酸、安息香酸、
メタンスルホン酸、ベンゼンスルホン酸など)との塩が
挙げられる。phosphoric acid, hydrobromic acid, sulfuric acid, etc.) or organic acids (acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid,
Examples include salts with methanesulfonic acid, benzenesulfonic acid, etc.).
次に本発明の化合物(りの製造法について述べる。Next, a method for producing the compound of the present invention will be described.
化合物(1)は、例えば、式(11)
[式中、Z′はハロゲンあるいはアルキルスルホニルオ
キシ又はアリールスルホニルオキシを示し、他の6記号
は前記と同意義。]で表4りされる化合物と、例えば、
式(III)
1−IZ(Ill)
[式中、Zは前記と同意義。]で表イっされる化合物、
又はその塩を反応させることにより製造することができ
る。Compound (1) is, for example, represented by the formula (11) [wherein Z' represents halogen, alkylsulfonyloxy, or arylsulfonyloxy, and the other 6 symbols have the same meanings as above. ] and the compounds listed in Table 4, for example,
Formula (III) 1-IZ(Ill) [wherein Z has the same meaning as above. ] Compounds represented by
Alternatively, it can be produced by reacting a salt thereof.
上記式(II)のZ′で示されるハロゲンとしてはたと
えば塩素、jA素、沃素などがあげられ、Z′で示され
るアルキルスルホニルオキシとしては、たとえばメタン
スルホニルオキシエタンスルホニルオキシなどが、アリ
ールスルホニルオキシとしてはたとえばベンゼンスルホ
ニルオキシの他パラメチルベンゼンスルホニルオキシ、
パラメトキシベンゼンスルホニルオキシ、パラニトロベ
ンゼンスルホニルオキシ、2.6−ジメチルベンゼンス
ルポニルオキシ、2,4.6−ドリメチルベンゼンスル
ホニルオキシなどの置換ベンゼンスルホニルオキシがあ
げられろ。Examples of the halogen represented by Z' in the above formula (II) include chlorine, jA element, and iodine, and examples of the alkylsulfonyloxy represented by Z' include methanesulfonyloxyethanesulfonyloxy, and arylsulfonyloxy. Examples include benzenesulfonyloxy, paramethylbenzenesulfonyloxy,
Examples include substituted benzenesulfonyloxy such as para-methoxybenzenesulfonyloxy, paranitrobenzenesulfonyloxy, 2,6-dimethylbenzenesulfonyloxy, and 2,4,6-drimethylbenzenesulfonyloxy.
この反応は塩基の存在下、溶媒を用いてまたは用いない
で行なわれる。This reaction is carried out in the presence of a base, with or without a solvent.
塩基としては、たとえば炭酸ナトリウム、炭酸カリウド
、炭酸リヂウム、水酸化ナトリウム、水酸化カリウム、
ナトリウムメトキシド、ナトリウムエトキシド、水素化
ナトリウムなどの無機塩基やピリジン、4−ジメチルア
ミノピリジン、トリエチルアミンなどの有機塩基があげ
られる。溶媒を使用ずろ場合、該溶媒としてはたとえば
メタノール。Examples of the base include sodium carbonate, potassium carbonate, lithium carbonate, sodium hydroxide, potassium hydroxide,
Examples include inorganic bases such as sodium methoxide, sodium ethoxide, and sodium hydride, and organic bases such as pyridine, 4-dimethylaminopyridine, and triethylamine. When no solvent is used, the solvent is, for example, methanol.
エタノール、プロパツール、イソプロパツール、nブタ
ノール、t−ブタノールなどの低級アルコール類、ジオ
キサン、エーテル、テトラヒドロフランなどのエーテル
類、トルエン、ベンゼン、キシレンなどの芳香族炭化水
素類、ジメヂルホルムアミド、ジメチルアセトアミド、
ヘキサメチルホス水ノドリアミドなどのアミド類、酢酸
エチル、酢酸ブチルなどのエステル類などがあげられる
。本反応は冷却下(0℃〜lO℃)、室温下(I l’
c〜40℃)、あるいは加熱下(41℃〜120℃)で
行うことができ、反応時間は、通常、lO分〜48時間
〜、好ましくは2〜6時間である。また使用する化合物
(III)の量は、通常、化合物(■1)に対して当モ
ルないし過剰m、好ましくは1.1〜5.0倍モルであ
る。さらに本反応は、必要に応じてヨウ化化合物、たと
えばヨウ化ナトリウム、ヨウ化カリウム、ヨウ化リチウ
ムなどの存在下に行ってもよい。Lower alcohols such as ethanol, propatool, isoproptool, n-butanol, t-butanol, ethers such as dioxane, ether, tetrahydrofuran, aromatic hydrocarbons such as toluene, benzene, xylene, dimedylformamide, dimethylacetamide ,
Examples include amides such as hexamethylphoshydrinodriamide, and esters such as ethyl acetate and butyl acetate. This reaction was carried out under cooling (0°C to 10°C) and at room temperature (I l'
C to 40°C) or under heating (41°C to 120°C), and the reaction time is usually 10 minutes to 48 hours, preferably 2 to 6 hours. The amount of compound (III) to be used is usually from equivalent molar to excess m, preferably from 1.1 to 5.0 times the molar amount of compound (1). Furthermore, this reaction may be carried out in the presence of an iodide compound such as sodium iodide, potassium iodide, lithium iodide, etc., if necessary.
尚、原料として用いられる化合物(n)は、たとえば下
記の反応によって製造することができる。Note that the compound (n) used as a raw material can be produced, for example, by the following reaction.
(1v)
、[
(■)
川原物質となる一般式(IV)の化合物は、特開昭58
−189163号公報に記載されている方法またはこれ
に準する方法により製造できる。(1v), [ (■) The compound of general formula (IV) which is a Kawahara substance is disclosed in Japanese Patent Application Laid-open No. 58
It can be produced by the method described in JP-A-189163 or a method similar thereto.
一般式(IV)で表わされる化合物を、自体公知の方法
、たとえば塩化ヂオニルで処理することにより、一般式
(V)で表わされる酸クロリドが得られる。本反応は、
室温下、または加熱下(50”0〜80℃)で行なわれ
る。ついで、酸クロリド(V)は通常のフリーゾルタラ
フッ反応の条件、たとえばジクロロメタンもしくは1.
2−ジクロロメタンを溶媒として塩化アルミニウムの存
在下に反応させることによって環化して化合物(Vl)
に導かれる。次に、(Vl)を通常のマンニッヒ反応の
条件、たとえばエタノールを溶媒として濃塩酸の存在下
に、パラホルムアルデヒドおよびピペリジン等のアミン
と反応させることによって化合物(■)に導くことがで
きる。本反応は、通常室温から溶媒(例、エタノール)
の沸点の間で行われる。次いで化合物(■)を、たとえ
ば四塩化炭素を溶媒としてアゾビスイソブチロニトリル
の存在下、N−ブロモスクシンイミドと還流上反応させ
ることにより化合物(n)に導くことかできる。The acid chloride represented by the general formula (V) is obtained by treating the compound represented by the general formula (IV) with a method known per se, for example, with dionyl chloride. This reaction is
The reaction is carried out at room temperature or under heat (50" to 80°C). The acid chloride (V) is then reacted under the usual free-sol fluoride reaction conditions, such as dichloromethane or 1.
Compound (Vl) is cyclized by reaction in the presence of aluminum chloride using 2-dichloromethane as a solvent.
guided by. Next, compound (■) can be obtained by reacting (Vl) with paraformaldehyde and an amine such as piperidine under conventional Mannich reaction conditions, for example, in the presence of concentrated hydrochloric acid using ethanol as a solvent. This reaction is usually carried out at room temperature using a solvent (e.g. ethanol).
is carried out between the boiling points of Compound (■) can then be reacted with N-bromosuccinimide under reflux, for example, in the presence of azobisisobutyronitrile using carbon tetrachloride as a solvent, thereby yielding compound (n).
本発明の化合物(1)は、ヒトを含む補乳動物において
酸素不足状態やごれに伴う症状を改滲する作用(例えば
抗アノキシア作用)を有しており、例えば脳保護剤とし
て有用である。Compound (1) of the present invention has an effect of ameliorating symptoms associated with oxygen deficiency and dirt in dairy animals including humans (eg, anti-anoxic effect), and is useful, for example, as a brain protective agent.
本発明の化合物(1)の有用な対象疾病としては、たと
えば脳卒中後遺症、脳梗塞後遺症8頭部外傷や脳手術に
伴う意識障害、老年性痴呆、決心症、心筋−梗塞などが
あげられ、これらの疾病の予防または治療に用いること
ができる。Diseases for which the compound (1) of the present invention is useful include, for example, aftereffects of cerebral infarction, disorders of consciousness associated with head trauma or brain surgery, senile dementia, determination syndrome, myocardial infarction, etc. It can be used for the prevention or treatment of diseases.
本発明の化合物はたとえば、錠剤、顆粒剤、カプセル剤
、注射剤、平削など種々の剤型でヒトを含む哺乳動物に
経口的、もしくは非経口的に投与しうる。投与mは対象
疾患の種類、症状、投与ルートなどにより差異はあるが
、一般的に成人においては、経1コ投与の場合、−日に
つき0.0111g−100111g、好ましくは0.
1〜101gである。The compound of the present invention can be administered orally or parenterally to mammals including humans in various dosage forms such as tablets, granules, capsules, injections, and tablets. The dosage m varies depending on the type of target disease, symptoms, administration route, etc., but in general, for adults, in the case of one oral administration, it is 0.0111 g to 100111 g per day, preferably 0.
It is 1 to 101 g.
2明の効果
本発明に係る化合物はヒトを含む哺乳動物において強い
抗アノキシア作用を有しており、たとえば脳卒中後遺症
、脳梗塞後遺症1頭部外傷や脳手術に伴う意識障害、老
年性痴呆、狭心症、心筋梗塞などの予防、治療に用いる
ことができ、医薬として有用なものである。2. Effects of the present invention The compound according to the present invention has a strong anti-anoxia effect in mammals including humans, such as post-stroke sequelae, cerebral infarction sequelae 1, consciousness disturbances associated with head trauma or brain surgery, senile dementia, and cerebral infarction sequelae. It can be used for the prevention and treatment of heart disease, myocardial infarction, etc., and is useful as a medicine.
実施例
以下において、実施例、参考例、製剤例および実験例を
あげ、本発明をより具体的に説明するが、本発明はこれ
らに限定されるものではない。EXAMPLES In the following, the present invention will be explained in more detail with reference to Examples, Reference Examples, Formulation Examples, and Experimental Examples, but the present invention is not limited thereto.
参考例1
6.6a−ジヒドロイソインドロ[2,1−a]キノリ
ン−5,11(5H)−ジオン
υ
(1) 3−オキソ−2−フェニルイソインドリン−1
−酢酸10.3gと塩化ヂオニル50gの混合物を70
℃で30分間加熱攪拌後、塩イビチオニルを減圧で留去
した。残渣をジク【Jロメタンに溶解した後、シリカゲ
ルディスクを通し、溶媒を減圧で留去した。残った固体
をジク〔lロメタンから再結晶して3−才キソー2−)
Jニルイソインドリン−1=酢酸り〔Jリド9.6gを
融点245−250℃(分解)の無色針状晶として得た
。Reference Example 1 6.6a-dihydroisoindolo[2,1-a]quinoline-5,11(5H)-dione υ (1) 3-oxo-2-phenylisoindoline-1
-70 g of a mixture of 10.3 g of acetic acid and 50 g of dionyl chloride
After heating and stirring at °C for 30 minutes, ibitionyl salt was distilled off under reduced pressure. The residue was dissolved in dichloromethane, passed through a silica gel disk, and the solvent was distilled off under reduced pressure. The remaining solid was diluted with dichloromethane (recrystallized from 1-romethane to give 3-year-old Kiso 2-).
J-nilisoindoline-1 = acetic acid [9.6 g of J-lido was obtained as colorless needles with a melting point of 245-250°C (decomposed).
(2)塩化アルミニウム15gの1.2−ジクロロ」”
、タン140+J!!澗液に(1)で得た3−オキソ−
2−フェニルイソインドリン−1=酢酸り【Jリド9.
5gを徐々に加えた。混合物を7忍で1時間攪拌した後
、水に加えた。生成物をジクロロメタンで抽出後、水洗
し、無水硫酸ナトリウムで乾燥した後、減圧で溶媒を留
去した。残った固体をツクC1ロメタンーエーテル(1
: I O(v/v))で再結J、1′して6.6a−
ノヒトロイソインドロ[2,1−a]キノリン−5,I
f(51−1)−ジオン7,9gを融点+72−173
°Cの無色結晶として得た。(2) 15 g of aluminum chloride 1,2-dichloro”
, Tan 140+J! ! Add 3-oxo- obtained in (1) to the starch solution.
2-Phenylisoindoline-1=acetic acid [J lido 9.
5g was added gradually. The mixture was stirred for 7 minutes for 1 hour and then added to water. The product was extracted with dichloromethane, washed with water, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. Remove the remaining solid by adding C1 lomethane-ether (1
: I O (v/v)) reconnect J, 1' and 6.6a-
nohytoleuisoindolo[2,1-a]quinoline-5,I
7.9 g of f(51-1)-dione with melting point +72-173
Obtained as colorless crystals at °C.
元、+;分析f%’、I C+ * tl + +
N Otとして(%) (%) (%)
計lγb’E: C77、lQ II 4.45
N 5.62実験値: C77,031+ 4.
44 N 56!f参考例2
参考例1と同様にして第1表に示す化合物が得られた。Original, +; analysis f%', I C+ * tl + +
As N Ot (%) (%) (%) Total lγb'E: C77, lQ II 4.45
N 5.62 Experimental value: C77,031+ 4.
44 N 56! fReference Example 2 The compounds shown in Table 1 were obtained in the same manner as in Reference Example 1.
(以 下 余 白)
参考例3
11b、12−ジヒドロ−5tl−イソイ、ン・ドロ[
2、I−b][2]ベンズアゼピン−7,13−ジオン
υ
(1) 2−(フェニルメチル)イソインドリン−1
゜3(2H)−ジオン4.6gをテトラヒドロフラン3
0yiとメタノール20hdlの混合溶液に溶解し、水
冷下、水素化ホウ素ナトリウム0.59gを徐々に加え
た。0℃で3時間攪拌後、水15071dlを加えた。(Margins below) Reference Example 3 11b,12-dihydro-5tl-isoy, n-doro[
2, I-b] [2] Benzazepine-7,13-dione υ (1) 2-(phenylmethyl)isoindoline-1
゜4.6g of 3(2H)-dione was dissolved in 3g of tetrahydrofuran.
The mixture was dissolved in a mixed solution of 0yi and 20 hdl of methanol, and 0.59 g of sodium borohydride was gradually added under water cooling. After stirring at 0°C for 3 hours, 15,071 dl of water was added.
生成した結晶をろ取し、水洗した後、減圧で乾燥して3
−ヒドロキシ−2−(フェニルメチル)イソインドリン
−1−オン4.3gを融点146℃の無色結晶として得
た。The formed crystals were collected by filtration, washed with water, and dried under reduced pressure.
4.3 g of -hydroxy-2-(phenylmethyl)isoindolin-1-one was obtained as colorless crystals with a melting point of 146°C.
元素分析値 C、sH、、N O,とじて(%)
(%) (%)
計算値: C75,30115,48N 5.85゜
実験値: C75,27II 5.43 N 5.
81(2)(1)で得た3−ヒドロキシ−2−(フェニ
ルメチル)イソインドリン−1−オン3gとエトキシカ
ルボニルメチリデントリフェニルホスホラン4.8gの
トルエン30kJl溶液を1時間還流した後、トルエン
を減圧で留去した。残った油状物と炭酸カリウム3gを
水8−とメタノール30−の混合溶液に溶解し、1時間
還流した。減圧でメタノールを留去した後、残渣を水3
0IR1に溶解し、10%塩酸で中和した。生成した結
晶をろ取し、水洗した後、減圧で乾燥して3−オキソ−
2−(フェニルメチル)イソインドリン−1−酢酸2.
5gを融点155−157℃の無色結晶として得た。Elemental analysis values C, sH,, NO, total (%)
(%) (%) Calculated value: C75,30115,48N 5.85° Experimental value: C75,27II 5.43 N 5.
After refluxing a toluene 30 kJl solution of 3 g of 3-hydroxy-2-(phenylmethyl)isoindolin-1-one obtained in 81(2)(1) and 4.8 g of ethoxycarbonylmethylidene triphenylphosphorane for 1 hour, Toluene was distilled off under reduced pressure. The remaining oil and 3 g of potassium carbonate were dissolved in a mixed solution of 8 parts of water and 30 parts of methanol, and the mixture was refluxed for 1 hour. After distilling off methanol under reduced pressure, the residue was diluted with water
0IR1 and neutralized with 10% hydrochloric acid. The formed crystals were collected by filtration, washed with water, and dried under reduced pressure to give 3-oxo-
2-(phenylmethyl)isoindoline-1-acetic acid2.
5 g were obtained as colorless crystals with a melting point of 155-157°C.
元素分析値 C、?11 、、N O3として(%)
(%) (%)
計算値: C70,58115,37N4.98実験
値: C72,39115,14N 5.04(3)
(2)で得た3−オキソ−2−(フェニルメチル)イソ
インドリン−1−酢酸3.5gを参考例1(1)と同様
に処理して3−オキソ−2−(フェニルメチル)イソイ
ンドリン−1−酢酸り、aリドとした後、参考例1(2
)と同様に処理して11b。Elemental analysis value C,? 11,, as N O3 (%)
(%) (%) Calculated value: C70,58115,37N4.98 Experimental value: C72,39115,14N 5.04(3)
3.5 g of 3-oxo-2-(phenylmethyl)isoindoline-1-acetic acid obtained in (2) was treated in the same manner as in Reference Example 1 (1) to obtain 3-oxo-2-(phenylmethyl)isoindoline. -1-acetic acid, a-lido, and then reference example 1 (2
) and processed in the same manner as 11b.
12−ジヒドロ−51−1−イソインドロ[2,1−b
][2]ベンズアゼピン−7,13−ジオン2.7gが
融点+99−200℃の無色針状晶として得られた。12-dihydro-51-1-isoindolo[2,1-b
] [2] 2.7 g of benzazepine-7,13-dione were obtained as colorless needles with a melting point of +99-200°C.
元素分析値 C+JI taN O*として(%)
(%) (%)
計算値: C77,551+ 4.98 N 5.
32実験値: C77,43+14.82 N 5
.41参考例4
7.8,14.14a−テトラヒドロイソインドロ[2
、I −cl[3]]ベンズアゾシンー5.13−すン
2−(2−フェニルエチル)イソインドール−1゜3(
211)−ジオンを原料として用い、参考例3と同様に
処理して?、8,14.14a−テトラヒドロイソイン
ドロ[2、I −cl[3]]ベンズアゾシンー513
−ジオンが融点19B−200℃の無色結晶として得ら
れた。Elemental analysis value C+JI taN O* (%)
(%) (%) Calculated value: C77,551+ 4.98 N 5.
32 Experimental value: C77,43+14.82 N 5
.. 41 Reference Example 4 7.8,14.14a-tetrahydroisoindolo[2
, I-cl[3]]benzazocine-5.13-sene-2-(2-phenylethyl)isoindole-1°3(
211)-Dione was used as a raw material and treated in the same manner as in Reference Example 3. , 8,14.14a-tetrahydroisoindolo[2,I-cl[3]]benzazosine-513
-dione was obtained as colorless crystals with a melting point of 19B-200C.
元素分析値 C、、II +sl’J O、として(%
) (%) (%)
計算値: C77,961! 5.45 N 5.
05実験値: C7?、83 115.38 N
5.04参考例5
6−メチルイソインドロ[2,1−a]キノリン−5、
If(5N)−ジオン
参考例(1)で得られた6、6a−ジヒドロイソインド
(J[2,1−a]キノリン−5,11(51−1)−
ジオン1.25g、ピペリジン0.55g、パラポルム
アルデヒド0.27gと濃塩酸0.02hj2の′エタ
ノールto!d溶液を2時間還流後、室温に冷却した。Elemental analysis value C,, II +sl'J O, (%
) (%) (%) Calculated value: C77,961! 5.45 N 5.
05 experimental value: C7? , 83 115.38 N
5.04 Reference Example 5 6-methylisoindolo[2,1-a]quinoline-5,
If(5N)-dione 6,6a-dihydroisoindo(J[2,1-a]quinoline-5,11(51-1)-
Dione 1.25g, piperidine 0.55g, parapolmaldehyde 0.27g and concentrated hydrochloric acid 0.02hj2' ethanol to! The solution was refluxed for 2 hours and then cooled to room temperature.
生成した沈殿をろ取し、エタノールで洗浄゛した後、ジ
クロロメタンから再結晶して融点26〇−261’Cの
黄色針状晶1.2gを得た。The formed precipitate was collected by filtration, washed with ethanol, and then recrystallized from dichloromethane to obtain 1.2 g of yellow needle crystals with a melting point of 260-261'C.
元素分析値 CI ? I■+ 、N Oxとして(%
) (%) (%)
計算値: C78,15114,24N 5.36実
験値: C77,87114,17N5.36参考例
6
参考例5と同様にして第2表に示す化合物が得られた。Elemental analysis value CI? I■+, as NOx (%
) (%) (%) Calculated value: C78,15114,24N 5.36 Experimental value: C77,87114,17N5.36 Reference Example 6 The compounds shown in Table 2 were obtained in the same manner as Reference Example 5.
(以 下 余 白)
参考例7
7.8−ジヒドロ−I4−メチルイソインドロ[2、I
−c][3]ベンズアゾシン−5,13−ジオンυ
(1)参考例5と同様にして、7,8−ジヒドロ−14
−メヂリデンイソインドロ[2、I −c][3]]ベ
ンズアゾシンー5.13−14a夏−1)−ジオンを融
点209−211’Cの無色結晶として得た。(Margin below) Reference Example 7 7.8-dihydro-I4-methylisoindolo[2,I
-c] [3] Benzazocine-5,13-dione υ (1) 7,8-dihydro-14
-Medilideneisoindolo[2,I-c][3]]benzazosine-5.13-14a summer-1)-dione was obtained as colorless crystals with a melting point of 209-211'C.
(2)上記化合物0.75gを触媒量のL−BuOK存
在下、エタノール15−中で50℃で2時間攪r1ミし
た。エタノールを減圧で留去した後、水を加え、生成物
をジクロロメタンで抽出した。抽出液は水洗後、無水酸
酸ナトリウムで乾燥し、溶媒を減圧で留去した。残った
固体をジクロロメタンエーテル(1:9(V/す)で再
結晶して融点234.5−235.5℃の無色結晶0.
72gを得た。(2) 0.75 g of the above compound was stirred for 2 hours at 50° C. in 15% ethanol in the presence of a catalytic amount of L-BuOK. After ethanol was distilled off under reduced pressure, water was added and the product was extracted with dichloromethane. The extract was washed with water, dried over sodium anhydride, and the solvent was distilled off under reduced pressure. The remaining solid was recrystallized with dichloromethane ether (1:9 (V/su)) to give colorless crystals with a melting point of 234.5-235.5°C.
72g was obtained.
元素分析値 C+d■+sN Otとして(%)
(%) (%)
計算値: C78,87115,23N4.84実験
値: C78,83115,13N 4.83参考例
8
6−ブロモメチルイソインドロ[2,1−a]キノリン
−5,II(511)−ジオン
タンから再結晶して融点237−241’C(分解)の
黄色針状晶1.5gを得た。Elemental analysis value C+d■+sN Ot (%)
(%) (%) Calculated value: C78,87115,23N4.84 Experimental value: C78,83115,13N 4.83 Reference example 8 6-bromomethylisoindolo[2,1-a]quinoline-5,II ( Recrystallization from 511)-diontane gave 1.5 g of yellow needles with a melting point of 237-241'C (decomposition).
元素分析値 C+tll +a13 rN Oxとして
(%) (%) (%)
計算値: C60,02112,96N 4.12実
験値: C60,301! 2.96 N 4.I
Q参考例9
参考°例8と同様にして第3表に示す化合物が得られた
。Elemental analysis value C+tll +a13 rN As Ox (%) (%) (%) Calculated value: C60,02112,96N 4.12 Experimental value: C60,301! 2.96 N 4. I
Q Reference Example 9 In the same manner as Reference Example 8, the compounds shown in Table 3 were obtained.
(以 下 余 白)
参考例5で得られた6−メチルイソインドロ[2、l−
a]キノリン−5,璽1(511)−ジオンl 、2g
とN−ブロモスクシンイミド0.84gと触媒mのアゾ
ビスイソブチロニトリルの四塩化炭素3〇−懸濁液を1
時間還流し、室温に冷却した。生成した結晶をろ取し、
エーテルで洗浄後、ジクロロメ実施例1
6−シメチルアミノメチルイソインドロし2.1a]キ
ノリン−5,1
1(5+−+)−ジオン
元素分針(F’l Cle Ll + a N t
O2として(%) (%) (%)
計算値: C74,981+ 5.30 N 9.
20実験値: C74,721! 5.18 N
9.10実施例2
実施例Iと同様にして第4表に示す化合物が得られた。(Left below) 6-methylisoindolo[2,l-
a] Quinoline-5, 1(511)-dione, 2g
and 0.84 g of N-bromosuccinimide and a 30-carbon tetrachloride suspension of azobisisobutyronitrile containing catalyst m.
It was refluxed for an hour and cooled to room temperature. Filter the formed crystals,
After washing with ether, dichloromethane Example 1 6-dimethylaminomethylisoindolo2.1a]quinoline-5,1 1(5+-+)-dione elemental minute hand (F'l Cle Ll + a N t
As O2 (%) (%) (%) Calculated value: C74,981+ 5.30 N 9.
20 Experimental value: C74,721! 5.18N
9.10 Example 2 The compounds shown in Table 4 were obtained in the same manner as in Example I.
参考例8で得られた6−ブロモメチルイソインド(7[
2,1−a]キノリン−5,I+(5H)−ジオン0.
6gとジメチルアミン塩酸塩0.43gと炭酸カリウム
0.98gのジオキサン20+J溶液との混合物を80
℃、2時間攪拌後、沈殿をろ過によって除き、減圧で溶
媒を留去した。残った油状物をシリカゲルカラムクロマ
トグラフィ(展開溶媒ニジクロロメタン、酢酸エチル−
10: l (v/v))にかけ、目的物の入った溶液
の溶媒を減圧で除いた。6-Bromomethylisoindo (7[
2,1-a]quinoline-5,I+(5H)-dione 0.
A mixture of 6g of dimethylamine hydrochloride, 0.43g of dimethylamine hydrochloride, and 0.98g of potassium carbonate in a dioxane 20+J solution was
After stirring at ℃ for 2 hours, the precipitate was removed by filtration, and the solvent was distilled off under reduced pressure. The remaining oil was purified by silica gel column chromatography (developing solvent: dichloromethane, ethyl acetate).
10:1 (v/v)), and the solvent of the solution containing the target product was removed under reduced pressure.
残った固体をジクロロメタンーヘキザン(1:10(V
/V))から再結晶して、融点+53−155°Cの黄
色針状晶0.5gを得た。The remaining solid was dissolved in dichloromethane-hexane (1:10 (V
/V)) to give 0.5 g of yellow needles with a melting point of +53-155°C.
(以 下 余 白)
製剤例1
(1) 6−シメチルアミノイソインドロ[2,Ia]
キノリン−5,11(5Ll)−ジオン 2g(2
)乳糖 148g(3) ト
ウモロコシ澱粉 45g(4)ステアリ
ン酸マグネシウム 5g(+)、(2)および
25gのトウモロコシ澱粉を混和し、10gのトウモロ
コシ澱粉と25〃Jの水とから作ったペーストととらに
顆粒化し、これに10gのトウモ〔1コシ澱粉と(4)
を加え、混合物を圧縮錠剤機で圧縮して、錠剤1錠当た
り(I)2mgを含aする直径611I11の錠剤10
00個を製造した。(Left below) Formulation example 1 (1) 6-dimethylaminoisoindolo[2,Ia]
Quinoline-5,11(5Ll)-dione 2g (2
) Lactose 148 g (3) Corn starch 45 g (4) Magnesium stearate 5 g (+), (2) and 25 g of corn starch were mixed together, and a paste made from 10 g of corn starch and 25 J of water was mixed with the tora. Granulate it and add 10g of corn [1 ounce of starch and (4)
was added and the mixture was compressed in a compression tablet machine to give 10 tablets of diameter 611I11 containing 2 mg of (I) per tablet.
00 units were manufactured.
製剤例2
(1) 6−シメチルアミノイソインドロ[2,13]
キノリン−5,11(5tl)−ジオン lOg(2
)乳糖 140g(3) ト
ウモロコシ澱粉 45g(4)ステアリ
ン酸マグネシウム 5g製剤例Iと同様にして
、錠剤1錠当たり(1)10a+gを含有する直径6m
1I+の錠剤100.0個を製造した。Formulation Example 2 (1) 6-dimethylaminoisoindolo[2,13]
Quinoline-5,11(5tl)-dione lOg(2
) Lactose 140 g (3) Corn starch 45 g (4) Magnesium stearate 5 g In the same manner as in Formulation Example I, each tablet contains (1) 10a+g of 6 m in diameter.
100.0 tablets of 1I+ were manufactured.
[実験例]
容ff1112の底なし臭気びんを装置として用い、上
方より混合ガス(N、98%、o、2%)を充満させ、
常に一定の流速で混合ガスを補填した。4〜5週齢のI
CI系雄性マウスを外気が装置内に入らぬよう速やかに
低部より入れ、呼吸が停止するまで観察した。本発明の
化合物20a+g/kgを5%アラビアゴム懸濁液とし
て、低酸素状態負荷30分前にマウスに腹腔内投与し、
呼吸が停止するまでの時間を生存時間として測定した。[Experiment example] A bottomless odor bottle with a capacity of ff1112 was used as a device, and a mixed gas (N, 98%, O, 2%) was filled from above.
The mixed gas was always supplemented at a constant flow rate. 4-5 week old I
A CI male mouse was immediately introduced from the bottom of the apparatus to prevent outside air from entering the apparatus, and observed until breathing ceased. Compound 20a+g/kg of the present invention was administered intraperitoneally to mice as a 5% gum arabic suspension 30 minutes before hypoxia challenge,
The survival time was measured as the time until breathing stopped.
本発明の化合物の抗アノキシア作用を、生存時間の平均
値(1群8匹)を対照群と比較することにより調べた。The anti-anoxic effect of the compounds of the present invention was investigated by comparing the average survival time (8 animals per group) with the control group.
その成績は対照群における平均値を100%とした時の
パーセント変化率で示した。The results were expressed as percent change when the average value in the control group was taken as 100%.
結果を第5表に示す。The results are shown in Table 5.
第5表 :統計学的な有意差(P<0.05)Table 5 : Statistically significant difference (P<0.05)
Claims (1)
、Zは置換されていてもよいアミノ基を示し、nは0〜
2の整数を示す。]で表わされる化合物またはその塩。[Claims] Formula ▲ Numerical formula, chemical formula, table, etc. ▼ [In the formula, X and Y each represent a hydrogen atom or a substituent, Z represents an optionally substituted amino group, and n is 0 ~
Indicates an integer of 2. ] or its salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19365688A JP2687463B2 (en) | 1988-08-02 | 1988-08-02 | Fused heterocyclic compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19365688A JP2687463B2 (en) | 1988-08-02 | 1988-08-02 | Fused heterocyclic compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0242078A true JPH0242078A (en) | 1990-02-13 |
JP2687463B2 JP2687463B2 (en) | 1997-12-08 |
Family
ID=16311578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP19365688A Expired - Fee Related JP2687463B2 (en) | 1988-08-02 | 1988-08-02 | Fused heterocyclic compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2687463B2 (en) |
-
1988
- 1988-08-02 JP JP19365688A patent/JP2687463B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2687463B2 (en) | 1997-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3224187B2 (en) | Cyclic amide derivative | |
US5576318A (en) | Benzimidazolone derivatives | |
JP5734628B2 (en) | Indole compounds and their pharmaceutical uses | |
RU2346945C2 (en) | Derivatives of n-heterocyclylmethylmenzamides, obtainment and application in therapy | |
US4686228A (en) | Quinoline therapeutic agents | |
EP1417206B1 (en) | Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | |
EP0464604B1 (en) | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | |
US6175015B1 (en) | Fused indolecarboxamides: dopamine receptor subtype specific ligands | |
EA015813B1 (en) | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
JPS6289679A (en) | Piperidine derivative | |
JPH08505381A (en) | Piperazine derivatives as 5-HT antagonists | |
JPH02138266A (en) | 6-phenyl-3-(piperazinylalkyl)-2,4(1h,3h)-pyrimidine dione derivative | |
CA1079277A (en) | 10(.omega.-(BENZOYLPIPERIDINYL)ALKYL) PHENOTHIAZINES | |
US6242448B1 (en) | Trisubstituted-oxazole derivatives as serotonin ligands | |
CN115362156A (en) | Muscarinic receptor 4 antagonists and methods of use | |
JPH0225481A (en) | 2-((4-piperadinyl)methyl)-1, 2, 3, 4-tetrahydroisoquinoline derivative and its production and adaptation thereof to treatment | |
IE59424B1 (en) | Diazinylpiperidine derivatives | |
JP2871811B2 (en) | 7-membered condensed ring compound | |
JPH0242078A (en) | Condensed heterocyclic compound | |
JP2571903B2 (en) | Novel aminoalkylchromone, method for producing the same, and pharmaceutical composition containing the same | |
EP1120410B1 (en) | Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors | |
WO2008033513A1 (en) | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | |
GB2162843A (en) | Piperazine derivatives | |
JPH04288073A (en) | Piperazine derivative | |
JPS62116557A (en) | Substituted benzyl lactam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |